Literature DB >> 10454106

Synergistic interactions between fenfluramine and phentermine.

P J Wellman1, T J Maher.   

Abstract

'Fen-phen' refers to the off-label combination of the appetite suppressants fenfluramine and phentermine. The rationale for the fen-phen combination was that the two drugs exerted independent actions on brain satiety mechanisms so that it was possible to use lower doses of each drug and yet retain a common action on suppressing appetite while minimizing adverse drug effects. The focus of the present review is to consider whether fenfluramine and phentermine exert actions that are additive in nature or whether these two drugs exhibit drug-drug synergism. The fen-phen combination results in synergism for the suppression of appetite and body weight, the reduction of brain serotonin levels, pulmonary vasoconstriction and valve disease. Fen-phen synergism may reflect changes in the pharmacokinetics of drug distribution, common actions on membrane ion currents, or interactions between neuronal release and reuptake mechanisms with MAO-mediated transmitter degradation. The synergism between fenfluramine and phentermine highlights the need to more completely understand the pharmacology and neurochemistry of appetite suppressants prior to use in combination pharmacotherapy for the treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454106     DOI: 10.1038/sj.ijo.0800920

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  10 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

4.  Pulmonary hypertension associated with use of phentermine.

Authors:  Woo-Dae Bang; Ji-Ye Kim; Hee-Tae Yu; Sung-Soo Cho; Ji-Yong Jang; Chang-Myung Oh; Boyoung Joung; Hyuk-Jae Chang
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

Review 5.  Brain-gut-microbiome interactions in obesity and food addiction.

Authors:  Arpana Gupta; Vadim Osadchiy; Emeran A Mayer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-08-27       Impact factor: 46.802

6.  Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat.

Authors:  Andrew J Grottick; Kevin Whelan; Erin K Sanabria; Dominic P Behan; Michael Morgan; Carleton Sage
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

Review 7.  GLP-1/glucagon receptor co-agonism for treatment of obesity.

Authors:  Miguel A Sánchez-Garrido; Sara J Brandt; Christoffer Clemmensen; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp
Journal:  Diabetologia       Date:  2017-07-21       Impact factor: 10.122

Review 8.  Glucagon Control on Food Intake and Energy Balance.

Authors:  Omar Al-Massadi; Johan Fernø; Carlos Diéguez; Ruben Nogueiras; Mar Quiñones
Journal:  Int J Mol Sci       Date:  2019-08-11       Impact factor: 5.923

Review 9.  Brain-Gut-Microbiome Interactions and Intermittent Fasting in Obesity.

Authors:  Juliette Frank; Arpana Gupta; Vadim Osadchiy; Emeran A Mayer
Journal:  Nutrients       Date:  2021-02-10       Impact factor: 5.717

Review 10.  Chemical Aspects of Human and Environmental Overload with Fluorine.

Authors:  Jianlin Han; Loránd Kiss; Haibo Mei; Attila Márió Remete; Maja Ponikvar-Svet; Daniel Mark Sedgwick; Raquel Roman; Santos Fustero; Hiroki Moriwaki; Vadim A Soloshonok
Journal:  Chem Rev       Date:  2021-03-16       Impact factor: 60.622

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.